Buy Opana ER 10mg

Buy Opana ER 10mg


Opana ER 10mg contains oxymorphone, a mu opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine.


Add to cart
Buy Now

Product Description


Opana ER 10mg


OPANA (oxymorphone hydrochloride) Opana ER 10mg, tablet is an opioid agonist available in 5 mg and 10 mg tablet strengths for oral administration. The chemical name for oxymorphone hydrochloride is 4, 5α-epoxy-3, 14-dihydroxy-17-methylmorphinan-6-one hydrochloride. The molecular weight is 337.80. The molecular formula is C17H19NO4. HCl and it has the following chemical structure.


OPANA (oxymorphone hydrochloride) Structural Formula Illustration

Oxymorphone hydrochloride is white to off white odorless powder, which is sparingly soluble in alcohol and ether, but freely soluble in water

The inactive ingredients in OPANA include: lactose monohydrate, magnesium stearate, and pregelatinized starch. In addition, the 5 mg tablets contain FD&C blue No. 2 aluminum lake. The 10 mg tablets contain D&C red No. 30 aluminum lake.


OPANA is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations Of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see WARNINGS AND PRECAUTIONS], reserve OPANA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

  • Have not been tolerated, or are not expected to be tolerated,
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia


Important Dosage And Administration Instructions

Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see WARNINGS AND PRECAUTIONS].

Initiate the dosing regimen for each patient individually, taking into account the patient’s severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see WARNINGS AND PRECAUTIONS].

Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with OPANA and adjust the dosage accordingly [see WARNINGS AND PRECAUTIONS].

OPANA should be administered on an empty stomach, at least one hour prior to or two hours after eating [see CLINICAL PHARMACOLOGY].

To avoid medication errors, prescribers and pharmacists must be aware that oxymorphone is available as both immediate-release 5 mg and 10 mg tablets and extended-release 5 mg and 10 mg tablets [see Dosage Forms and Strengths].

Initial Dosage

Use Of OPANA As The First Opioid Analgesic

Initiate treatment with OPANA in a dosing range of 10 to 20 mg every 4 to 6 hours as needed for pain.

Do not initiate treatment with doses higher than 20 mg because of the potential serious adverse reactions [see Clinical Studies].

Conversion From Other Opioids To OPANA

There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of OPANA. It is safer to underestimate a patient’s 24-hour OPANA dosage than to overestimate the 24-hour OPANA dosage and manage an adverse reaction due to overdose.

For conversion from other opioids to OPANA, physicians and other healthcare professionals are advised to refer to published relative potency information, keeping in mind that conversion ratios are only approximate. In general, it is safest to start OPANA therapy by administering half of the calculated total daily dose of OPANA in 4 to 6 equally divided doses, every 4-6 hours. The initial dose of Opana ER 10mg can be gradually adjusted until adequate pain relief and acceptable side effects have been achieved.

Conversion From Parenteral Oxymorphone To OPANA

Given OPANA’s absolute oral bioavailability of approximately 10%, patients receiving parenteral oxymorphone may be converted to OPANA by administering 10 times the patient’s total daily parenteral oxymorphone dose as OPANA, in four or six equally divided doses (e.g., [IV dose x 10] divided by 4 or 6). For example, approximately 10 mg of OPANA four times daily may be required to provide pain relief equivalent to a total daily IM dose of 4 mg oxymorphone. Due to patient variability with regard to opioid analgesic response, upon conversion patients should be closely monitored to ensure adequate analgesia and to minimize side effects.

Conversion From OPANA To Extended-Release Oxymorphone

The relative bioavailability of OPANA compared to extended-release oxymorphone is unknown, so conversion to extended-release tablets must be accompanied by close observation for signs of excessive sedation and respiratory depression.

Dosage Modifications In Patients With Mild Hepatic Impairment

OPANA is contraindicated in patients with moderate or severe hepatic impairment. Use OPANA with caution in patients with mild hepatic impairment, starting with the lowest dose (e.g., 5 mg) and titrating slowly while carefully monitoring for signs of respiratory and central nervous system depression [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].

Dosage Modifications In Patients With Renal Impairment

Use OPANA with caution in patients with creatinine clearance rates less than 50 mL/min., starting with the lowest dose (e.g., 5 mg) and titrating slowly while carefully monitoring for signs of respiratory and central nervous system depression [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].

Dosage Modifications In Geriatric Patients

Exercise caution in the selection of the starting dose of Opana ER 10mg for an elderly patient by starting with the lowest dose (e.g., 5 mg) and titrate slowly while carefully monitoring for signs of respiratory and central nervous system depression [see Use in Specific Populations].

Dosage Modifications With Concomitant Use With Central Nervous System Depressants

OPANA, like all opioid analgesics, should be started at one-third to one-half of the usual dose in patients who are concurrently receiving other central nervous system (CNS) depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, and alcohol, because respiratory depression, hypotension and profound sedation, coma or death may result [see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS]. When combined therapy with any of the above medications is considered, the dose of one or both agents should be reduced.

Titration And Maintenance Of Therapy

Individually titrate OPANA to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving OPANA to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see WARNINGS AND PRECAUTIONS]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of  changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the OPANA dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Discontinuation Of OPANA

When a patient who has been taking OPANA regularly and may be physically dependent no longer requires therapy with OPANA, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue OPANA in a physically-dependent patient [see

WARNINGS AND PRECAUTIONSDrug Abuse and Dependence].


Dosage Forms And Strengths

Tablets 5 mg: blue, round, convex tablet debossed with E612 over 5 on one side and plain on the other.

Tablets 10 mg: red, round, convex tablet debossed with E613 over 10 on one side and plain on the other.

Storage And Handling

OPANA (oxymorphone hydrochloride) tablets are supplied as follows:

5 mg Tablet

Blue, round, convex tablets debossed with E612 over 5 on one side and plain on the other.

Bottles of 100 tablets with child-resistant closure NDC 63481-612-70
Unit-Dose package of 100 tablets (5 blister cards of 20 tablets, not child-resistant, for hospital use only) NDC 63481-612-75

10 mg Tablet

Red, round, convex tablets debossed with E613 over 10 on one side and plain on the other.

Bottles of 100 tablets with child-resistant closure NDC 63481-613-70
Unit-Dose package of 100 tablets (5 blister cards of 20tablets, not child-resistant, for hospital use only) NDC 63481-613-75



The following serious adverse reactions are described, or described in greater detail, in other sections:

  • Addiction, Abuse, and Misuse [see WARNINGS AND PRECAUTIONS]
  • Life-Threatening Respiratory Depression [see WARNINGS AND PRECAUTIONS]
  • Neonatal Opioid Withdrawal Syndrome [see WARNINGS AND PRECAUTIONS]
  • Interactions with Benzodiazepines and Other CNS Depressants [see WARNINGS AND PRECAUTIONS]
  • Anaphylaxis, Angioedema, and Other Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
  • Adrenal Insufficiency [see WARNINGS AND PRECAUTIONS]
  • Severe Hypotension [see WARNINGS AND PRECAUTIONS]
  • Gastrointestinal Adverse Reactions [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 591 patients were treated with OPANA in controlled clinical trials. The clinical trials consisted of patients with acute post-operative pain (n=557) and cancer pain (n=34) trials.

The following table lists adverse reactions that were reported in at least 2% of patients receiving OPANA in placebo-controlled trials (acute post-operative pain (N=557)).

Reviews (0)


There are no reviews yet.

Be the first to review “Buy Opana ER 10mg”